 |
Positive Safety Profile, Too
Threshold Nails PFS Endpoint In TH-302 Pancreatic Cancer Trial
Threshold Pharmaceuticals Inc. saw shares rocket as high as 88 percent Tuesday morning after the company reported its Phase IIb study evaluating TH-302 in advanced pancreatic cancer hit its primary endpoint.